[Meta] the receptor rule is doing its job and people should stop complaining
the receptor rule is doing its job and people should stop complaining, and here is what changes in practice if it goes ahead.
Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.
GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.
Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.
Corrections welcome, especially the pedantic ones. Pedantry is how this board earns its reputation.
best — the order this archive was captured in
Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.
Is that from a human study or a preclinical model?
Not convinced by the linearity assumption. Dose-response in this class is not linear and the trials show it.
What was the exposure in that experiment relative to therapeutic?
I would not read that in vitro number across to a person. The conditions are nothing like physiological.
Is that from a human study or a preclinical model?
Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.
Read the primary paper after arguing about the summary for a fortnight. The discussion section said almost the opposite of what the thread had concluded.
the peripheral and central stories are not in competition
Do you have the paper, or a summary of it?
albumin binding is most of the half-life story
Agreed — the incretin effect is the load-bearing concept and everything downstream reads differently once you have it.
GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite regulation. The central component is the better explanation for sustained intake reduction.
Push back: a receptor being expressed in a tissue does not tell you the agonist reaches it at therapeutic exposure.
- 1Glucose-dependent insulin secretion is why hypoglycaemia risk is low as…6 comments in this branch · started by u/laila_almeida